ATE501169T1 - Lactoferrin-peptide, geeignet als in die zelle eindringende peptide - Google Patents

Lactoferrin-peptide, geeignet als in die zelle eindringende peptide

Info

Publication number: ATE501169T1
Authority: AT; Austria
Prior art keywords: peptide; peptides; cell; penetrating; lactoferrin
Prior art date: 2005-12-30

Application number

AT06806526T

Other languages

English (en)

Inventor

Roland Brock

Rainer Fischer

Mariola Fotin-Mleczek

Hansjoerg Hufnagel

Norbert Windhab

Original Assignee

Evonik Roehm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-30

Filing date

2006-10-25

Publication date

2011-03-15

2006-10-25 Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE501169T1 publication Critical patent/ATE501169T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
102000020313 Cell-Penetrating Peptides Human genes 0.000 title abstract 2
108010051109 Cell-Penetrating Peptides Proteins 0.000 title abstract 2
102000010445 Lactoferrin Human genes 0.000 title 1
108010063045 Lactoferrin Proteins 0.000 title 1
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title 1
229940078795 lactoferrin Drugs 0.000 title 1
235000021242 lactoferrin Nutrition 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
150000001413 amino acids Chemical class 0.000 abstract 2
101000798100 Bos taurus Lactotransferrin Proteins 0.000 abstract 1
101000798114 Homo sapiens Lactotransferrin Proteins 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
102000050459 human LTF Human genes 0.000 abstract 1
150000002632 lipids Chemical class 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
230000000149 penetrating effect Effects 0.000 abstract 1
235000018102 proteins Nutrition 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
150000003384 small molecules Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Toxicology (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT06806526T 2005-12-30 2006-10-25 Lactoferrin-peptide, geeignet als in die zelle eindringende peptide ATE501169T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP05028755		2005-12-30
PCT/EP2006/010271 WO2007076904A1 (en)	2005-12-30	2006-10-25	Peptides useful as cell-penetrating peptides

Publications (1)

Publication Number	Publication Date
ATE501169T1 true ATE501169T1 (de)	2011-03-15

Family

ID=37491778

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06806526T ATE501169T1 (de)	2005-12-30	2006-10-25	Lactoferrin-peptide, geeignet als in die zelle eindringende peptide

Country Status (16)

Country	Link
US (3)	US20100061932A1 (de)
EP (1)	EP1966240B3 (de)
JP (1)	JP5264502B2 (de)
KR (1)	KR101317100B1 (de)
CN (1)	CN101395180B (de)
AT (1)	ATE501169T1 (de)
AU (1)	AU2006332193B2 (de)
BR (1)	BRPI0620806B8 (de)
CA (1)	CA2646833C (de)
DE (1)	DE602006020617D1 (de)
ES (1)	ES2361621T7 (de)
IL (1)	IL192131A (de)
MX (1)	MX2008008548A (de)
PL (1)	PL1966240T6 (de)
SI (1)	SI1966240T1 (de)
WO (1)	WO2007076904A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102005051366A1 (de)	2005-10-25	2007-04-26	Degussa Gmbh	Drug Delivery Systeme
EP2050461A1 (de)	2007-10-19	2009-04-22	PharmaSurgics in Sweden AB	Peptide basierend auf der menschlichen Lactoferrinsequenz und ihre Verwendung
EP2090584A1 (de) *	2008-02-13	2009-08-19	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Identifikation eines neuartigen Zystein-reichen Peptids zur Zellenpenetration
ES2671024T3 (es) *	2008-02-28	2018-06-04	Toray Industries, Inc.	Composición farmacéutica para administración transnasal
EP2445536B1 (de)	2009-06-22	2016-06-08	Burnham Institute for Medical Research	Verfahren und zusammensetzungen mit peptiden und proteinen mit c-terminalen elementen
EP2514760B1 (de) *	2009-12-14	2015-10-21	National University Corporation Hokkaido University	Peptide zur übertragung von zellpermeabilität an eine lipidmembranstruktur
WO2011084061A1 (en)	2010-01-08	2011-07-14	Universitair Medisch Centrum St. Radboud	Cpp (cell penetrating peptide) and its uses
FR2955773B1 (fr) *	2010-02-01	2017-05-26	Commissariat Energie Atomique	Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
AU2010364538B2 (en) *	2010-11-26	2016-04-14	Evonik Operations Gmbh	Human lactoferrin derived peptide for use as an antigen masking agent
CN102174078A (zh) *	2011-01-10	2011-09-07	中国药科大学	肿瘤细胞选择性穿膜肽的应用
CN102091036A (zh) *	2011-01-10	2011-06-15	中国药科大学	一种含有抗肿瘤药物的复合脂质体及其制备方法和用途
CN102153629B (zh) *	2011-01-20	2013-07-24	华中科技大学	一种短肽及其应用
WO2012118778A1 (en)	2011-02-28	2012-09-07	Sanford-Burnham Medical Research Institute	Truncated car peptides and methods and compositions using truncated car peptides
WO2012166585A2 (en)	2011-05-31	2012-12-06	Airware, Inc.	Re-calibration of ab ndir gas sensors
US10179801B2 (en)	2011-08-26	2019-01-15	Sanford-Burnham Medical Research Institute	Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
CN102988295B (zh) *	2011-09-09	2015-07-29	复旦大学	一种穿膜肽修饰的纳米粒及其制备方法
CN102993296A (zh) *	2011-09-14	2013-03-27	广州格拉姆生物科技有限公司	牛乳铁蛋白肽及其制备方法
WO2013052058A1 (en) *	2011-10-07	2013-04-11	Morehouse School Of Medicine	Antimicrobial compositions and methods of use thereof
US8669226B2 (en)	2011-10-07	2014-03-11	Morehouse School Of Medicine	Antimicrobial compositions and methods of use thereof
US12083158B2 (en)	2011-10-07	2024-09-10	Morehouse School Of Medicine	Antibacterial compositions, methods of making and use thereof
DE102011055229A1 (de)	2011-11-10	2013-05-16	Evonik Degussa Gmbh	Verfahren zur Bereitstellung von Regelleistung mit einem Energiespeicher unter Ausnutzung von Toleranzen bei der Bestimmung der Frequenzabweichung
DE102011055231A1 (de) *	2011-11-10	2013-05-16	Evonik Industries Ag	Verfahren zur Bereitstellung von Regelleistung
CN116549655A (zh)	2011-11-24	2023-08-08	苏州宝时得电动工具有限公司	多肽序列设计及其在多肽介导的siRNA传递中的应用
CN103169982B (zh) *	2011-12-23	2015-05-20	中国科学院上海药物研究所	生物活性肽修饰的纳米银及其制备方法和用途
CN103382217B (zh) *	2012-12-11	2015-05-27	任发政	穿膜肽和药物组合物及其制备方法和应用
CN105491982B (zh) *	2013-08-12	2019-09-10	3M创新有限公司	用于增强透皮递送的肽
WO2015075747A1 (en) *	2013-11-19	2015-05-28	Council Of Scientific And Industrial Research	Cell-penetrating peptide for biomolecule delivery
CA2933561A1 (en)	2013-12-12	2015-06-18	Life Technologies Corporation	Membrane-penetrating peptides to enhanced transfection and compositions and methods for using same
CN103784406A (zh) *	2014-01-20	2014-05-14	同济大学	一种偶联穿膜肽和mmp酶切位点的纳米颗粒
JP6588039B2 (ja) *	2014-05-28	2019-10-09	エボニックレームゲゼルシャフトミットベシュレンクテルハフツングＥｖｏｎｉｋＲｏｅｈｍＧｍｂＨ	ナノ粒子
CN107207627B (zh) *	2015-02-27	2022-05-24	学校法人常翔学园	具有膜透过性肽链的多糖衍生物
KR101647804B1 (ko) *	2015-06-24	2016-08-11	한국과학기술연구원	신규 세포투과 펩타이드 및 이의 용도
CN108456254B (zh) *	2017-02-20	2021-06-01	中国科学院上海药物研究所	一种tcs-穿膜肽-肿瘤蛋白酶底物肽融合蛋白、其制备方法和用途
EP3628047A1 (de)	2017-05-02	2020-04-01	Sanford Burnham Prebys Medical Discovery Institute	Tumorassoziiertes monozyten-/makrophagenbindendes peptid und verfahren zur verwendung davon
CN108101966B (zh) *	2017-12-26	2020-10-27	暨南大学	基于细胞穿膜肽的氧化还原敏感多肽及其在疫苗载体中的应用
WO2019214939A1 (en)	2018-05-08	2019-11-14	Evonik Röhm Gmbh	Nanoparticle comprising a bio-resorbable polyester, a hydrophilic polymer and an acylated human lactoferrin-derived peptide
CN111499759B (zh) *	2019-01-31	2022-12-20	上海科技大学	一种具有细胞穿膜性的锌指蛋白-乳铁蛋白融合蛋白质及其制备与应用
US12583888B2 (en)	2019-02-04	2026-03-24	University Of Tartu	Bi-specific extracellular matrix binding peptides and methods of use thereof
CN110078834B (zh) *	2019-05-05	2021-07-30	华中科技大学	一种类短肽、辅助透膜剂及其应用
WO2021093881A1 (zh) *	2019-11-14	2021-05-20	上海鑫湾生物科技有限公司	用于调控酸性环境免疫应答的组合物、其制备方法和用途
WO2021195522A2 (en) *	2020-03-27	2021-09-30	ALASTIN Skincare, Inc.	Compositions and methods relating to pigmentation
KR20240163740A (ko)	2022-03-30	2024-11-19	에보니크 오퍼레이션즈 게엠베하	세포 내로의 폴리뉴클레오티드의 전달을 위한 양이온성 지질 및 폴리(락틱-코-글리콜산)로 구성된 제제
JP2025535128A (ja) *	2022-10-13	2025-10-22	スティッチングラドバウドウニヴェルシテールメディシュセントルム	カーゴ及びインテレクチン１に結合する標的化部分を含む複合体
IL320934A (en)	2022-12-01	2025-07-01	Univ Yale	Stimuli-responsive traceless engineering platform for intracellular payload delivery

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5633076A (en) *	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
EP1493825A3 (de)	1990-06-11	2005-02-09	Gilead Sciences, Inc.	Verfahren zur Herstellung von Nukleinsäureliganden
JP2818056B2 (ja) *	1990-09-07	1998-10-30	森永乳業株式会社	抗菌性ペプチドおよび抗菌剤
JP3207535B2 (ja) *	1992-08-07	2001-09-10	森永乳業株式会社	抗酸化剤
JP3312946B2 (ja)	1993-03-04	2002-08-12	雪印乳業株式会社	ウイルス感染・増殖抑制剤
JP2001504448A (ja)	1996-08-30	2001-04-03	フュルステ，イェンス，ペーター	核酸の鏡面対称選択および進化
US5849902A (en)	1996-09-26	1998-12-15	Oligos Etc. Inc.	Three component chimeric antisense oligonucleotides
US5989912A (en)	1996-11-21	1999-11-23	Oligos Etc. Inc.	Three component chimeric antisense oligonucleotides
DE19742706B4 (de)	1997-09-26	2013-07-25	Pieris Proteolab Ag	Lipocalinmuteine
SE9804614A0 (en) *	1998-07-06	2000-01-07	A+ Science Invest Ab	New peptides and use thereof
AU4656999A (en) *	1998-07-15	2000-02-07	Samyang Genex Corporation	Mass production method of lactoferrin polypeptide from yeast and useful microorganism thereof
US6423509B1 (en) *	1998-07-15	2002-07-23	Samyang Genex Corporation	Pichia pastoris strain for producing lactoferrin and methods of use
GB9818938D0 (en) *	1998-08-28	1998-10-21	Alpharma As	Bioactive peptides
DE19956568A1 (de)	1999-01-30	2000-08-17	Roland Kreutzer	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6399570B1 (en) *	1999-02-05	2002-06-04	Agennix, Inc.	Antimicrobial/endotoxin neutralizing polypeptide
NZ553687A (en)	2000-03-30	2010-03-26	Whitehead Biomedical Inst	RNA sequence-specific mediators of RNA interference

2006
- 2006-10-25 SI SI200631008T patent/SI1966240T1/sl unknown
- 2006-10-25 CA CA2646833A patent/CA2646833C/en active Active
- 2006-10-25 ES ES06806526T patent/ES2361621T7/es active Active
- 2006-10-25 JP JP2008547861A patent/JP5264502B2/ja not_active Expired - Fee Related
- 2006-10-25 AU AU2006332193A patent/AU2006332193B2/en active Active
- 2006-10-25 KR KR1020087015786A patent/KR101317100B1/ko active Active
- 2006-10-25 EP EP06806526A patent/EP1966240B3/de active Active
- 2006-10-25 WO PCT/EP2006/010271 patent/WO2007076904A1/en not_active Ceased
- 2006-10-25 AT AT06806526T patent/ATE501169T1/de active
- 2006-10-25 DE DE602006020617T patent/DE602006020617D1/de active Active
- 2006-10-25 BR BRPI0620806A patent/BRPI0620806B8/pt active IP Right Grant
- 2006-10-25 CN CN200680049953.0A patent/CN101395180B/zh active Active
- 2006-10-25 PL PL06806526T patent/PL1966240T6/pl unknown
- 2006-10-25 MX MX2008008548A patent/MX2008008548A/es active IP Right Grant
- 2006-10-25 US US12/159,226 patent/US20100061932A1/en not_active Abandoned
2008
- 2008-06-12 IL IL192131A patent/IL192131A/en active IP Right Grant
2012
- 2012-07-25 US US13/557,706 patent/US9403884B2/en active Active
2015
- 2015-12-01 US US14/955,696 patent/US20160151504A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN101395180B (zh)	2016-06-22
DE602006020617D1 (de)	2011-04-21
IL192131A (en)	2011-10-31
MX2008008548A (es)	2008-09-10
IL192131A0 (en)	2008-12-29
ES2361621T7 (es)	2012-06-14
EP1966240B1 (de)	2011-03-09
US20100061932A1 (en)	2010-03-11
BRPI0620806B8 (pt)	2022-07-05
JP2009521908A (ja)	2009-06-11
JP5264502B2 (ja)	2013-08-14
US9403884B2 (en)	2016-08-02
CA2646833A1 (en)	2007-07-12
CA2646833C (en)	2019-07-30
WO2007076904A1 (en)	2007-07-12
CN101395180A (zh)	2009-03-25
PL1966240T3 (pl)	2011-08-31
PL1966240T6 (pl)	2012-05-31
BRPI0620806B1 (pt)	2017-12-05
EP1966240B3 (de)	2011-12-28
KR101317100B1 (ko)	2013-10-15
AU2006332193B2 (en)	2012-06-28
US20160151504A1 (en)	2016-06-02
KR20080091120A (ko)	2008-10-09
US20130108662A1 (en)	2013-05-02
BRPI0620806A2 (pt)	2011-11-22
ES2361621T3 (es)	2011-06-20
SI1966240T1 (sl)	2011-06-30
EP1966240A1 (de)	2008-09-10
AU2006332193A1 (en)	2007-07-12

Legal Events

Date

Code

Title

Description

2011-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1966240

Country of ref document: EP

Publication	Publication Date	Title
ATE501169T1 (de)	2011-03-15	Lactoferrin-peptide, geeignet als in die zelle eindringende peptide
Newmeyer et al.	1990	An N-ethylmaleimide-sensitive cytosolic factor necessary for nuclear protein import: requirement in signal-mediated binding to the nuclear pore.
NZ598159A (en)	2013-08-30	Transport molecules using reverse sequence hiv-tat polypeptides
MX357674B (es)	2018-07-18	Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos.
EP3756690A3 (de)	2021-03-17	Membranpenetrierende peptide zur erhöhung der transfektion und zusammensetzungen und verfahren zur verwendung davon
ATE445709T1 (de)	2009-10-15	Glycoproteinsynthese
ATE352559T1 (de)	2007-02-15	Verfahren zur verminderung der immunogenität von proteinen
WO2007064917A3 (en)	2008-03-13	Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
NZ504752A (en)	2002-10-25	Hydrophobically-modified protein compositions (particularly hedgehog proteins)
EP2728004A3 (de)	2014-07-23	Bakterientoxinimpfstoff
DE602006016468D1 (de)	2010-10-07	Verfahren zur abgabe von fusionspolypeptid in eine zelle
BRPI0410562A (pt)	2006-06-20	molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
ATE485386T1 (de)	2010-11-15	Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
WO2004067555A3 (en)	2005-12-29	Protein and peptide delivery to mammalian cells in vitro
ATE529445T1 (de)	2011-11-15	Biokinetik zur schnellen beseitigung von polypeptiden
Wang et al.	2025	Overview of Peptides and Their Potential Roles in Skin Health and Beauty
PE20020875A1 (es)	2002-10-31	Peptidos supersegregables en procedimientos para su produccion y para la mejora en paralelo de las formas exportadas de uno o mas de otros peptidos de interes
ATE532793T1 (de)	2011-11-15	Verfahren zur herstellung von molekülen mit verminderter immunogenität
KR102305279B1 (ko)	2021-09-28	카스파제 억제제의 존재하에 진핵 세포 용해물을 이용한 무세포 단백질 합성방법 및 장치 및 상기 합성방법에서 합성된 단백질의 수율 및/또는 안정성을 향상시키기 위한 카스파제 억제제의 용도
WO2007089334A3 (en)	2008-01-10	Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein
ATE490266T1 (de)	2010-12-15	In zellen eindringende peptide als träger für moleküle
ES2421558T3 (es)	2013-09-03	Anticuerpos específicos de cáncer y proteínas de superficie celular
BR0303362A (pt)	2005-07-19	Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal
WO2023114515A3 (en)	2023-08-17	Anti-pilra antibodies, uses thereof, and related methods and reagents
ATE496133T1 (de)	2011-02-15	Affinitätspolypeptid zur reinigung von rekombinanten proteinen